The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 99)
LRRK2 Research Grant, 2016
Promising Outcomes of Original Grant:
Our initial grant, led by Dr. Susan Taylor, focused on the structural organization of a protein called LRRK2, an enzyme that transfers small chemical groups called phosphates to other proteins. These phosphates are signals that regulate cellular functions. In Parkinson's disease (PD), LRRK2 is altered by an exchange of some of its basic building blocks called a...
Researchers: Stefan Knapp, PhD
Priority Target Award, 2016
Genetic mutations that alter the function of the LRRK2 protein increase the risk of developing a form of Parkinson's disease (PD). Age and other environmental factors combine with genetic risk factors to result in the disease. One of the pathological hallmarks of PD is the presence of protein clumps that appear in brain cells, composed of alpha-synuclein and LRRK2. Recent work has...
Researchers: Austen James Milnerwood, PhD
Target Validation Awards, 2016
Astrocytes are important cells in the brain. They play a major role in brain inflammation and neurodegeneration; however, their role in Parkinson's disease (PD) is unclear. The protein alpha-synuclein, which is associated with PD pathology, can trigger the reactivity of astrocytes. The goal of the project is to understand the molecular and functional consequences of alpha-synuclein...
Researchers: Laurent Roybon, PhD
Target Validation, 2015
Numerous studies have highlighted a potential role of neuroinflammation in Parkinson's disease whereby the immune cells of the brain called microglia may produce inflammatory factors that are toxic to dopamine neurons. Cannabinoid type-2 receptors (CB2) are largely found on activated microglia and are increased in people with and models of Parkinson's disease. Th...
Therapeutic Pipeline Program, 2015
The alpha-synuclein protein forms oligomers (protein clumps) that cause toxicity in the brains of individuals with Parkinson's disease (PD). We have developed methods that can measure these toxic changes in brain cells grown in a petri dish. We aim to identify a drug candidate capable of preventing these toxic effects.
We hypothesize that drug candidates can effectively...
Researchers: Susan M. Catalano, PhD